Liquidia (NASDAQ:LQDA) Stock Price Down 4.7%

Shares of Liquidia Co. (NASDAQ:LQDAGet Free Report) dropped 4.7% during mid-day trading on Tuesday . The company traded as low as $12.70 and last traded at $12.70. Approximately 412,124 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 873,157 shares. The stock had previously closed at $13.33.

Analyst Upgrades and Downgrades

Several analysts have weighed in on LQDA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Liquidia in a report on Monday, June 3rd. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Liquidia in a research note on Wednesday, May 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

View Our Latest Analysis on LQDA

Liquidia Stock Performance

The stock has a market capitalization of $937.95 million, a P/E ratio of -8.06 and a beta of 0.25. The stock has a 50-day moving average price of $13.07 and a two-hundred day moving average price of $12.99.

Liquidia (NASDAQ:LQDAGet Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. The company had revenue of $2.97 million during the quarter, compared to analysts’ expectations of $4.31 million. Equities analysts anticipate that Liquidia Co. will post -1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In related news, CEO Roger Jeffs sold 8,360 shares of the stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $121,888.80. Following the completion of the transaction, the chief executive officer now directly owns 826,985 shares in the company, valued at approximately $12,057,441.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Liquidia news, CFO Michael Kaseta sold 3,136 shares of the stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $45,722.88. Following the sale, the chief financial officer now directly owns 315,045 shares in the company, valued at approximately $4,593,356.10. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Roger Jeffs sold 8,360 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $121,888.80. Following the sale, the chief executive officer now owns 826,985 shares of the company’s stock, valued at $12,057,441.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,653 shares of company stock valued at $270,409. 31.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently made changes to their positions in the business. Patient Square Capital LP bought a new stake in shares of Liquidia during the first quarter valued at approximately $105,942,000. Vanguard Group Inc. raised its stake in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after acquiring an additional 43,352 shares during the period. Kynam Capital Management LP lifted its stake in Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares during the last quarter. Farallon Capital Management LLC bought a new stake in shares of Liquidia during the 1st quarter worth approximately $30,311,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Liquidia during the fourth quarter valued at $12,331,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

See Also

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.